Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Phase 3 Trial of CP-675,206 Versus Either Dacarbazine or Temozolomide in Patients Without Prior Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				A3671009 NCT00257205


2.		CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				A3671004 NCT00075192


3.		CP-675,206 In Patients With Advanced Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				A3671002 NCT00086489


4.		Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				A3671015 NCT00312975


5.		Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				A3671014 NCT00313794


6.		Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				A3671011 NCT00431275

Last Modified: 9/11/2008 First Published: 5/29/2008


7.		Study of the Effects of Immune-Modulating Therapies on Tissue Expression of Indoleamine 2, 3 dioxygenase in Patients With Untreated Acute or Chronic Hepatitis C, Metastatic Melanoma, or Crohn Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Biomarker/Laboratory analysis				Completed				No age specified				NCI				VU-VICC-MEL-0651 VICC-MEL-0651, VU-VICC-060614

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute